All In Biotech

Drug Trial Radar · NCT07950215

A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia

A Phase 3, Multi-center, Randomized, Open-Label, Active-Controlled, Efficacy and Safety Study of AND017 to Treat Anemia in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Feb 1, 2027

Primary completion

Dec 1, 2027

Study completion Jun 1, 2028

Sponsor

Lead sponsor
Kind Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of AND017 in non-dialysis-dependent (NDD)-CKD patients with anemia compared with the active control, erythropoietin stimulating agents (ESA).

Conditions

  • Anemia Due to Chronic Kidney Disease

Interventions

  • AND017 capsulesDrug

    AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patients

  • ESADrug

    ESA injection and dose based on package insert and local practice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The mean Hb levels averaged over Week 25-29Time frame: Week 25 to Week 29

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.